Back to search
FDAFDA · Food and drugs·Recall number Z-1033-2024

BD BBL Sensi Disc Meropenem- 10 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231703 and 231704®

Published February 14, 2024 · Recall initiated: January 8, 2024

Summary

FDA records medical device Class II recall Z-1033-2024, published February 14, 2024 and initiated January 8, 2024. Recalling firm: Becton Dickinson & Co.; Status: Ongoing; Reported quantity: 2,363,168 total units; Lot: Catalog No. 231703 UDI-DI 00382902317036 Lots 2147649 9065664; Catalog No. 231704® UDI-DI 30382902317044 Lots 2213585 3061281 3090652 3213825 2187975 2213583. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

There is a possibility of reproducibility, accuracy, and/or QC failures in antibiotic susceptibility testing (AST) for H. influenzae. This may cause product discard, delayed results, or additional adverse diagnostic outcomes, such as a delay in diagnosis, the selection of inappropriate antibiotics, or extended duration of antibiotic exposure and the treatment process.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Becton Dickinson & Co.
Distributor
Domestic distribution nationwide. International distribution worldwide.
Lot
Catalog No. 231703 UDI-DI 00382902317036 Lots 2147649 9065664; Catalog No. 231704® UDI-DI 30382902317044 Lots 2213585 3061281 3090652 3213825 2187975 2213583
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was BD BBL Sensi Disc Meropenem- 10 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231703 and 231704® recalled?

Yes. FDA published recall Z-1033-2024 on February 14, 2024. Reported hazard: There is a possibility of reproducibility, accuracy, and/or QC failures in antibiotic susceptibility testing (AST) for H. influenzae. This may cause product discard, delayed results, or additional adverse diagnostic outcomes, such as a delay in diagnosis, the selection of inappropriate antibiotics, or extended duration of antibiotic exposure and the treatment process.

What should I do if I have this product?

Voluntary: Firm initiated · Letter